NCT00138593View on ClinicalTrials.gov

Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

vildagliptin

Trial Locations (1)

Unknown

Novartis Pharmaceuticals, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY